ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology
BOSTON, Nov. 17, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that it will host a conference call and webcast slide presentation on Monday, November 20, 2017 at 10:15 a.m. ET to discuss updated clinical data from the Company's controlled human interleukin-12 (hIL-12) gene therapy candidate for brain cancer to be presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), held Nov. 16 - 19 in San Francisco.
In addition to members of the ZIOPHARM management team, joining the conference call will be key thought leaders and study investigators Antonio Chiocca, M.D., Ph.D., Professor of Neurosurgery at Harvard Medical School, Surgical Director, Center for Neuro-oncology at Dana-Farber Cancer Institute, and Chairman of Neurosurgery and Co-Director of the Institute for the Neurosciences at Brigham and Women's Hospital, and Stewart Goldman, M.D., Division Head Hematology-Oncology, Neuro-Oncology & Stem Cell Transplantation at Ann & Robert H. Lurie Children's Hospital in Chicago.
The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The conference ID number is 8089664. To access the accompanying slides and live webcast, or the subsequent archived recording, visit the "Investors & Media" section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website for two weeks.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
RheoSwitch Therapeutic System® and RTS® are registered trademarks of Intrexon Corporation.